Literature DB >> 8384765

The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription.

S D Vernon1, C E Hart, W C Reeves, J P Icenogle.   

Abstract

Epidemiologic studies show an association between infection with human immunodeficiency virus type 1 (HIV-1) and human papillomavirus (HPV) associated anogenital disease. To investigate possible molecular mechanisms of HIV-1 modulation of HPV expression, we studied the effect of an HIV-1 regulatory protein, tat1, on gene expression directed by the upstream regulatory region (URR) of HPV type 16 (HPV 16). HPV 16 URR-directed chloramphenicol acetyltransferase (CAT) expression driven by the native HPV 16 promoter (P97) was increased in the presence of tat1 alone. Tat1 also reversed E2-mediated repression of P97-directed CAT expression. E2 mediated CAT expression with URR constructs containing the SV40 promoter was enhanced when tat1 and E2 were cotransfected. Using a cervical carcinoma cell line (SiHa), E2 enhancement of URR-directed gene expression was elevated in the presence of extracellular tat1 or during cocultivation with HIV-1-infected cells. These results show HIV can modulate HPV gene expression in cell culture and that the increased rate of HPV-associated cervical disease in asymptomatic HIV-seropositive women may result from HPV-HIV molecular interactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384765     DOI: 10.1016/0168-1702(93)90077-z

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  28 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 2.  The role of viral and bacterial pathogens in gastrointestinal cancer.

Authors:  Michael Selgrad; Peter Malfertheiner; Lucia Fini; Ajay Goel; C Richard Boland; Luigi Ricciardiello
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

3.  HIV and human papillomavirus as independent risk factors for cervical neoplasia in women with high or low numbers of sex partners.

Authors:  S D Vernon; E R Unger; M A Piper; S T Severin; S Z Wiktor; P D Ghys; D L Miller; I R Horowitz; A E Greenberg; W C Reeves
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

4.  Association of human papillomavirus with HIV and CD4 cell count in women with high or low numbers of sex partners.

Authors:  M A Piper; S T Severin; S Z Wiktor; E R Unger; P D Ghys; D L Miller; I R Horowitz; A E Greenberg; W C Reeves; S D Vernon
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

5.  Mechanisms of viral infections associated with HIV: workshop 2B.

Authors:  S M Tugizov; J Y Webster-Cyriaque; S Syrianen; A Chattopadyay; H Sroussi; L Zhang; A Kaushal
Journal:  Adv Dent Res       Date:  2011-04

Review 6.  Human papillomaviruses and cervical neoplasia. II. Interaction of HPV with other factors.

Authors:  C S Herrington
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

Review 7.  Gynecologic issues in the HIV-infected woman.

Authors:  Helen E Cejtin
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

8.  The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research.

Authors:  Lara F Bratcher; Vikrant V Sahasrabuddhe
Journal:  Infect Agent Cancer       Date:  2010-05-12       Impact factor: 2.965

9.  Epidemiology of HPV in HIV-positive and HIV-negative fertile women in Cameroon, West Africa.

Authors:  Andrew J Desruisseau; Delf Schmidt-Grimminger; Edith Welty
Journal:  Infect Dis Obstet Gynecol       Date:  2010-02-09

10.  Assessing the relationship between HIV infection and cervical cancer in Côte d'Ivoire: a case-control study.

Authors:  Georgette Adjorlolo-Johnson; Elizabeth R Unger; Edith Boni-Ouattara; Kadidiata Touré-Coulibaly; Chantal Maurice; Suzanne D Vernon; Marcel Sissoko; Alan E Greenberg; Stefan Z Wiktor; Terence L Chorba
Journal:  BMC Infect Dis       Date:  2010-08-17       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.